222 related articles for article (PubMed ID: 32357562)
1. Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton's Tyrosine Kinase Inhibitor.
Lee KW; Lee WH; Han BS; Lee JH; Doo EK; Kim JH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357562
[No Abstract] [Full Text] [Related]
2. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
3. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
Sakthivel S; Habeeb SKM
J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
[TBL] [Abstract][Full Text] [Related]
4. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis.
Pery N; Rizvi NB; Shafiq MI
J Mol Model; 2020 Aug; 26(9):235. PubMed ID: 32808204
[TBL] [Abstract][Full Text] [Related]
5. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
[TBL] [Abstract][Full Text] [Related]
8. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
Liu J; Chen C; Wang D; Zhang J; Zhang T
Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B
Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711
[TBL] [Abstract][Full Text] [Related]
10. Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies.
Alrouji M; Benjamin LS; Alhumaydhi FA; Al Abdulmonem W; Baeesa SS; Rehan M; Shahwan M; Shamsi A; Akhtar A
Sci Rep; 2023 Oct; 13(1):17684. PubMed ID: 37848584
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.
Lee E; Cho H; Lee DK; Ha J; Choi BJ; Jeong JH; Ryu JH; Kang JS; Jeon R
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126415
[TBL] [Abstract][Full Text] [Related]
12. 4D-QSAR and MIA-QSAR study on the Bruton's tyrosine kinase (Btk) inhibitors.
Ma W; Wang Y; Chu D; Yan H
J Mol Graph Model; 2019 Nov; 92():357-362. PubMed ID: 31450065
[TBL] [Abstract][Full Text] [Related]
13. Structural mechanism for Bruton's tyrosine kinase activation at the cell membrane.
Wang Q; Pechersky Y; Sagawa S; Pan AC; Shaw DE
Proc Natl Acad Sci U S A; 2019 May; 116(19):9390-9399. PubMed ID: 31019091
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 1-Amino-1
Ma C; Li Q; Zhao M; Fan G; Zhao J; Zhang D; Yang S; Zhang S; Gao D; Mao L; Zhu L; Li W; Xu G; Jiang Y; Ding Q
J Med Chem; 2021 Nov; 64(21):16242-16270. PubMed ID: 34672559
[TBL] [Abstract][Full Text] [Related]
15. Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Angst D; Gessier F; Janser P; Vulpetti A; Wälchli R; Beerli C; Littlewood-Evans A; Dawson J; Nuesslein-Hildesheim B; Wieczorek G; Gutmann S; Scheufler C; Hinniger A; Zimmerlin A; Funhoff EG; Pulz R; Cenni B
J Med Chem; 2020 May; 63(10):5102-5118. PubMed ID: 32083858
[TBL] [Abstract][Full Text] [Related]
16. Bayesian machine learning to discover Bruton's tyrosine kinase inhibitors.
Wang J; Ran T; Chen Y; Lu T
Chem Biol Drug Des; 2020 Oct; 96(4):1114-1122. PubMed ID: 31855311
[TBL] [Abstract][Full Text] [Related]
17. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
[TBL] [Abstract][Full Text] [Related]
18. A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation.
Lopez-Tapia F; Lou Y; Brotherton-Pleiss C; Kuglstatter A; So SS; Kondru R
Bioorg Med Chem Lett; 2019 May; 29(9):1074-1078. PubMed ID: 30857747
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.
Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717
[TBL] [Abstract][Full Text] [Related]
20. Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors.
Zou Y; Xiao J; Tu Z; Zhang Y; Yao K; Luo M; Ding K; Zhang Y; Lai Y
Bioorg Med Chem Lett; 2016 Jul; 26(13):3052-3059. PubMed ID: 27210433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
